Medimpact

## STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### INDOMETHACIN SUSPENSION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
INDOMETHACIN	INDOCIN		36490	GPI-14	
				(66100030001805)	

### **GUIDELINES FOR USE**

- 1. Does the patient have **ONE** of the following diagnoses?
  - Moderate to severe rheumatoid arthritis (including acute flares of chronic disease)
  - Moderate to severe ankylosing spondylitis
  - Moderate to severe osteoarthritis
  - Acute painful shoulder (bursitis, tendinitis)
  - Acute gouty arthritis

If yes, continue to #2. If no, do not approve. **DENIAL TEXT:** See the denial text at the end of the guideline.

- 2. Does the patient meet ALL of the following criteria?
  - The patient had a trial of generic indomethacin capsules
  - The patient cannot swallow indomethacin capsules

If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #40mL per day.** If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **INDOMETHACIN SUSPENSION (Indocin)** requires the following rule(s) be met for approval:

- A. You have ONE of following diagnoses:
  - 1. Moderate to severe rheumatoid arthritis (a type of joint condition)
  - 2. Moderate to severe ankylosing spondylitis (a type of joint condition)
  - 3. Moderate to severe osteoarthritis (a type of joint condition)
  - 4. Acute painful shoulder (such as bursitis, tendinitis)
  - 5. Acute gouty arthritis (a type of joint condition)
- B. You had a trial of generic indomethacin capsules
- C. You cannot swallow indomethacin capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

# CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

## INDOMETHACIN SUSPENSION

## RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Indocin.

## REFERENCES

• Indocin [Prescribing Information]. Whitby, Ontario: Patheon Inc., April 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 04/01/23 Created: 11/22 Client Approval: 02/23

P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.